Inspire is sponsoring the large-scale Phase III program in the US, which has now been initiated. Inspire's partner, Santen Pharmaceutical Co., Ltd. , is developing INS365 Ophthalmic in Japan and nine other Asian countries, where a Phase I study is currently being conducted. Ophthalmic is a small-molecule drug that stimulates the P2Y 2 receptor, a key mediator of mucosal hydration and lubrication. INS365 Ophthalmic eye drops are expected to enhance the eye's natural cleansing and protective systems by stimulating the release of salt, water, mucus and other natural tear components, providing lubrication of the ocular surface. INS316 Diagnostic has been studied in over 300 patients through a series of clinical trials in which it has been shown to be safe and well tolerated.
Samples are highly enriched in lung cells of interest.
The first of two parallel Phase III clinical trials was initiated in May, 2001. This trial is being conducted in 600 patients at 24 sites across the US and Costa Rica. The trial is designed to evaluate the effectiveness of INS316 in diagnosing lung cancer. Additional Respiratory Diagnostic Information INS37217 Respiratory for the treatment of cystic fibrosis is a second-generation P2Y 2 agonist with an extended duration of action in laboratory studies, making it an attractive product candidate for cystic fibrosis. The molecule is designed to enhance the lung's innate mucosal hydration and mucociliary clearance mechanisms, which in cystic fibrosis patients are seriously impaired due to a genetic defect.